Bristol-Myers Squibb Earnings: What Investors Should Watch

Bristol-Myers Squibb (NYSE:BMY) will report earnings before markets open on Thursday, July 25th. Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.

Here is your Cheat Sheet to Bristol-myers Squibb Earnings:

Earnings Expectations: Analysts expect earnings of $0.44 per share on revenues of $4.05 billion. Currently, the company’s P/E ratio stands at 49.77.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.48 to a profit $0.47. For the current year, the average estimate is a profit of $1.8, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Bristol-myers Squibb has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 20,597 18,808 19,484 21,244 17,621
Diluted EPS ($) 2.63 5.34 1.79 2.16 1.16

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 4,443.00 3,736.00 4,191.00 3,831.00
Diluted EPS ($) 0.38 -0.43 0.56 0.37

Past Performance:
Bristol-myers Squibb has beat analyst estimates 1 time in the past four quarters. This is not consistent enough to get bullish yet.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]